This is a promotional website intended for UK Healthcare Professionals (HCPs) only.

Prescribing information and adverse event reporting information can be found below.

Log in Place an order
About Products Disease Awareness Supply Resources Events Contact

Disease protection

Measures can be taken to reduce the risk of contracting chikungunya

Travellers can reduce their risk of chikungunya infection by getting vaccinated (see below) and taking precautions against mosquito bites.5,7

Environmental protection

Stay in accommodation with air-conditioned or well-screened rooms, or use bed nets and aerosol room insecticides.14

–

Exposure

To reduce the risk of bites, avoid outdoor activities from dusk to dawn when mosquitoes are most active. Aedes mosquitoes are particularly aggressive during the day, especially at dawn and dusk, and tend to bite multiple people.15

–

Barrier protection

Use insect repellent on both skin and clothing, and wear loose, long-sleeved shirts and long trousers when outdoors.14

–

Vaccination can help protect adults against disease caused by CHIKV16

Help protect travellers from chikungunya with IXCHIQ®Powder and solvent for solution for injection. Chikungunya vaccine (live).

IXCHIQ® is indicated in the UK for active immunisation for the prevention of disease caused by CHIKV in individuals 18 years and older.7

Learn more about IXCHIQ®

View Prescribing InformationFurther information on SMPC Further information on PIL

Place an order

Useful links

For healthcare professionals:

UK Health Security Agency TravelHealthPro World Health Organization U.S. Centers for Disease Control and Prevention

To recommend to travellers:

TravelHealthPro GOV.UK Foreign travel advice

References

  1. World Health Organization. Global Chikungunya Epidemiology Update. June 2025. Available at: https://cdn.who.int/media/docs/default-source/documents/epp/ezh/chikungunya-epidemiology-update_11june2025.pdf?sfvrsn=ffddcf60_4&download=true. Accessed: June 2025.
  2. World Health Organization. Chikungunya factsheet. April 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/chikungunya. Accessed: June 2025.
  3. Ryan SJ, Carlson CJ, Mordecai EA, Johnson LR. Global expansion and redistribution of Aedes-borne virus transmission risk with climate change. PLoS Negl Trop Dis. 2019;13(3):e0007213.
  4. Tjaden NB, Cheng Y, Beierkuhnlein C, Thomas SM. Chikungunya beyond the tropics: Where and when do we expect disease transmission in Europe? Viruses. 2021;13(6):1024.
  5. Centers for Disease Control and Prevention. Chikungunya. CDC Yellow Book 2026. April 2025. Available at: https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/chikungunya.html. Accessed: June 2025.
  6. Paixão ES, Rodrigues LC, Costa M da CN, et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2018;112(7):301-316.
  7. IXCHIQ. Summary of Product Characteristics. March 2025. Available at: https://www.medicines.org.uk/emc/product/100652/smpc. Accessed: June 2025.
  8. Zurbia-Flores GM, Reyes-Sandoval A, Kim YC. Chikungunya virus: Priority pathogen or passing trend? Vaccines (Basel). 2023;11(3):568.
  9. European Centre for Disease Prevention and Control. Chikungunya virus disease – Annual Epidemiological Report for 2022. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/CHIK_AER_2022_report.pdf.
  10. Rezza G, Nicoletti L, Angelini R, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet. 2007;370(9602):1840-1846.
  11. UK Health Security Agency. Travel-associated infections in England, Wales and Northern Ireland: 2024. March 2025. Available at: https://www.gov.uk/government/publications/travel-associated-infections/travel-associated-infections-in-england-wales-and-northern-ireland-2024. Accessed: June 2025.
  12. Micheleto JPC, Melo KA, Veloso FCS, Kassar SB, Oliveira MJC. Risk factors for mortality in patients with chikungunya: A systematic review and meta-analysis. Tropical Medicine & International Health. 2025;30(4):235-245.
  13. Essackjee K, Goorah S, Ramchurn SK, Cheeneebash J, Walker-Bone K. Prevalence of and risk factors for chronic arthralgia and rheumatoid-like polyarthritis more than 2 years after infection with chikungunya virus. Postgrad Med J. 2013;89(1054):440-447.
  14. NHS Scotland. Mosquito Bite Avoidance - Fit for Travel. Available at: https://www.fitfortravel.nhs.uk/advice/malaria/mosquito-bite-avoidance. Accessed: June 2025.
  15. Britannica. Aedes | Description, Life Cycle, & Disease Transmission. April 2025. Available at: https://www.britannica.com/animal/Aedes. Accessed: June 2025.
  16. Schneider M, Narciso-Abraham M, Hadl S, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;401(10394):2138-2147.

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Valneva UK Ltd Medical Information department on Tel: 01506 446608 or via email: safety@valneva.com

2026 - Please use a modern browser